Based on data from the past 90 days ending December 12, 2025, Sagimet Biosciences's three largest insider shareholders are Chief Legal & Admin. Officer Elizabeth Rozek (193.58K shares), Chief Medical Officer Eduardo Bruno Martins (106.94K shares), Executive Chairman George Kemble (81.00K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Enterprise Associates 13 Lp New | 3,000,275 | 31 Jan, 2024 | |
| Partners 13, Limited Partnership Nea | 3,000,275 | 31 Jan, 2024 | |
| Pbd Associates, Llc Kpcb | 1,899,475 | 20 Jul, 2023 | |
| Jinzi Jason Wu | 1,654,701 | 20 Jul, 2023 | |
| David Happel | President & CEO | 689,722 | 23 Jul, 2025 |
| Elizabeth Rozek | Chief Legal & Admin. Officer | 193,581 | 06 Nov, 2025 |
| Beth C Seidenberg | 131,643 | 20 Jul, 2023 | |
| Eduardo Bruno Martins | Chief Medical Officer | 106,936 | 23 Jul, 2025 |
| George Kemble | Executive Chairman | 81,005 | 21 Nov, 2025 |
| Thierry Chauche | Chief Financial Officer | 17,000 | 07 Feb, 2025 |
| Patrick J Kerins | 13,139 | 31 Jan, 2024 | |
| Merdad Parsey | 12,794 | 20 Jul, 2023 | |
| Forest Baskett | 11,300 | 31 Jan, 2024 | |
| Scott D Sandell | 6,997 | 31 Jan, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 20 Nov, 2025 | George Kemble | Series A Common Stock | D | 37,688 | $7.69 | 81,005 | D | S |
| 04 Nov, 2025 | Elizabeth Rozek | Series A Common Stock | A | 9,855 | $0.00 | 193,581 | D | A |
| 21 Jul, 2025 | Elizabeth Rozek | Series A Common Stock | D | 10,780 | $9.13 | 183,726 | D | S |
| 21 Jul, 2025 | David Happel | Series A Common Stock | D | 65,478 | $9.13 | 689,722 | D | S |
| 21 Jul, 2025 | Eduardo Bruno Martins | Series A Common Stock | D | 8,277 | $9.13 | 106,936 | D | S |
| 21 Jul, 2025 | David Happel | - | - | 689,722 | D | |||
| 06 Feb, 2025 | Eduardo Bruno Martins | Series A Common Stock | A | 34,000 | $0.00 | 115,213 | D | A |
| 06 Feb, 2025 | Thierry Chauche | - | - | 17,000 | D | |||
| 06 Feb, 2025 | Elizabeth Rozek | Series A Common Stock | A | 34,000 | $0.00 | 194,506 | D | A |
| 06 Feb, 2025 | David Happel | Series A Common Stock | A | 116,000 | $0.00 | 755,200 | D | A |
| 06 Feb, 2025 | Thierry Chauche | Series A Common Stock | A | 17,000 | $0.00 | 17,000 | D | A |
| 23 Jul, 2024 | George Kemble | Series A Common Stock | D | 23,625 | $3.17 | 118,693 | D | S |
| 19 Jul, 2024 | George Kemble | Series A Common Stock | D | 14,062 | $3.10 | 142,318 | D | S |
| 19 Jul, 2024 | Eduardo Bruno Martins | Series A Common Stock | D | 8,357 | $3.10 | 81,213 | D | S |
| 19 Jul, 2024 | George Kemble | - | - | 142,318 | D | |||
| 19 Jul, 2024 | Elizabeth Rozek | Series A Common Stock | D | 10,914 | $3.10 | 160,506 | D | S |
| 26 Mar, 2024 | David Happel | - | - | 639,200 | D | |||
| 26 Mar, 2024 | David Happel | Series A Common Stock | A | 12,100 | $5.27 | 639,200 | D | P |
| 29 Jan, 2024 | Enterprise Associates 13 Lp New | - | - | 3,000,275 | D | |||
| 29 Jan, 2024 | Partners 13, Limited Partnership Nea | Series A Common Stock | D | 850,000 | $0.00 | 3,000,275 | I | J |